Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMOT4039A
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
DMOT4039A is an investigational antibody-drug conjugate (ADC) designed for the treatment of cancers expressing mesothelin, such as pancreatic and ovarian cancer. It consists of a humanized IgG1 anti-mesothelin monoclonal antibody (h7D9.v3 or MMOT0530A) linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. The ADC targets mesothelin-expressing tumor cells, delivering MMAE directly to these cells to disrupt microtubules and induce cell death. Clinical studies have shown that DMOT4039A has antitumor activity and a tolerable safety profile in patients with unresectable pancreatic or platinum-resistant ovarian cancer[2][3][5][6].
- Other names
- h7D9.v3 (antibody component)MMOT0530A (antibody component)
02
Targets
Mesothelin
Beyond the preview
Go deeper on DMOT4039A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMOT4039A.